velpatasvir

E409693

NS5A inhibitor antiviral drug direct-acting antiviral hepatitis C treatment small molecule

Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.

Try in SPARQL Jump to: Surface forms Statements Referenced by

All labels observed (1)

Label	Occurrences
velpatasvir canonical	1

Statements (48)

Predicate	Object
instanceOf	NS5A inhibitor ⓘ antiviral drug ⓘ direct-acting antiviral ⓘ hepatitis C treatment ⓘ small molecule ⓘ
adverseEffect	anemia (when combined with ribavirin) ⓘ fatigue ⓘ headache ⓘ insomnia ⓘ nausea ⓘ
approvalYear	2016 ⓘ
approvedBy	European Medicines Agency ⓘ Food and Drug Administration ⓘ surface form: U.S. Food and Drug Administration
ATCCode	J05AP55 ⓘ
bindsTo	human plasma proteins ⓘ
cautionIn	patients with decompensated cirrhosis ⓘ patients with severe renal impairment ⓘ
contraindicatedWith	strong CYP2B6 inducers ⓘ strong CYP2C8 inducers ⓘ strong CYP3A4 inducers ⓘ strong P-glycoprotein inducers ⓘ
developedBy	Gilead Sciences (board member) ⓘ surface form: Gilead Sciences
drugClass	antiviral for systemic use ⓘ
effectiveIn	patients with compensated cirrhosis ⓘ patients without cirrhosis ⓘ
hasMolecularTarget	hepatitis C virus replication complex ⓘ
hasPregnancyCategory	use only if potential benefit justifies potential risk ⓘ
hasTradeName	Epclusa ⓘ
indicatedFor	chronic hepatitis C genotype 1 ⓘ chronic hepatitis C genotype 2 ⓘ chronic hepatitis C genotype 3 ⓘ chronic hepatitis C genotype 4 ⓘ chronic hepatitis C genotype 5 ⓘ chronic hepatitis C genotype 6 ⓘ pan-genotypic hepatitis C treatment ⓘ
isComponentOf	sofosbuvir-velpatasvir fixed-dose combination ⓘ
legalStatus	prescription-only ⓘ
metabolizedBy	CYP2B6 ⓘ CYP2C8 ⓘ CYP3A4 ⓘ
outcome	sustained virologic response in many patients ⓘ
reduces	hepatitis C viral load ⓘ
routeOfAdministration	oral ⓘ
takenOnceDailyWith	sofosbuvir ⓘ
targets	HCV NS5A protein ⓘ
typicalTreatmentDuration	12 weeks ⓘ
usedFor	treatment of chronic hepatitis C virus infection ⓘ
usedWith	Sovaldi ⓘ surface form: Sofosbuvir

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Gilead Sciences (board member) → developed → velpatasvir ⓘ

subject surface form: Gilead Sciences